A report from GHTC and Policy Cures Research examines how US federal funding for global health R&D is delivering impact both abroad and at home.

Search the GHTC website

News

News
PATH/Will Boase
March 26, 2014

Recommendations from GHTC policy report highlighted in FierceBiotechResearch

Key policy recommendations from GHTC’s report Innovation for a changing world: The role of US leadership in global health R&D are highlighted in an article in FierceBiotechResearch, including the need for sustained funding for global health R&D and stronger roles for the US Agency for International Development and US Food and Drug Administration in advancing development of and access to new global health products.

Read time: 2 minutes / External link
PATH/Will Boase
March 26, 2014

Science Codex covers GHTC policy report launch

GHTC’s press release on the launch of its report Innovation for a changing world: The role of US leadership in global health R&D was picked up by Science Codex. The article highlights key findings from the report and policy recommendations for the US government, particularly the need for sustained funding and a strategic, coordinated approach to global health R&D. The article notes that recent budget cuts at the US National Institutes of Health—the largest funder of global health R&D—could jeopardize future progress against HIV/AIDS, tuberculosis, malaria, and neglected tropical diseases.

Read time: 5 minutes / External link
PATH/Patrick McKern
March 26, 2014

Voice of America interviews GHTC director on findings from GHTC policy report

Voice of America reports on GHTC’s report Innovation for a changing world: The role of US leadership in global health R&D, highlighting key findings and the report’s recommendations for US policymakers. GHTC Director Kaitlin Christenson is quoted, discussing the importance of sustained, reliable funding for global health R&D.

Read time: 4 minutes / External link
PATH/Gabe Bienczycki
March 13, 2014

Research Roundup: What we’re reading this week

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

Written by Nick Taylor / GHTC
Read time:
In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week. More detailed information about the President’s fiscal year (FY) 2015 budget requests to Congress was released this week, resulting in a mixed bag for global health research and development. The Congressional Budget Justifications—annual presentations to Congress to justify requests for funding—help shed more light on the administration’s priorities for FY 2015. The results of a Phase III clinical trial for a rotavirus vaccine were released this week and published in The Lancet. The vaccine candidate—which was tested in India—was found to be safe and have modest efficacy of 53.6 percent against severe rotavirus gastroenteritis. New data shows that the number of principle investigators with National Institutes of Health (NIH) funding dropped significantly last year—between 500 and 1000 researchers. While NIH funding has been on the decline over the last several years, the most significant drop in researchers was due to last year’s sequestration. GHTC member Seattle BioMed has a received a $9.8 million grant from the National Institute of Allergy and Infectious Diseases to develop two new vaccines against HIV and AIDS. Seattle BioMed will lead a consortium of academic institutions working together on the project, including Rockefeller University, the University of Washington, Seattle Children’s Hospital, and the Fred Hutchinson Cancer Research Center.